Dioctyl phthalate

Synonyms: DNOP; Di-n-octyl phthalate; Phthalic acid dioctyl ester
Dioctyl phthalate (DNOP) 是一种增塑剂,可导致肝脏内丙氨酸转氨酶 (ALT) 和碱性磷酸酶 (ALP) 活性升高以及肾脏内肌酐和尿素水平升高,并破坏肠道微生物群落稳态,增加致病菌丰度而降低 Lactobacillus 等有益菌丰度,还可导致小鼠肝脏、脾脏和肾脏出现显著且呈剂量依赖性的炎症反应。
产品编号: MS-V60831 纯度: 99.40% CAS No.: 117-84-0 分子式: C24H38O4 分子量: 390.56
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Dioctyl phthalate (DNOP) 是一种增塑剂,可导致肝脏内丙氨酸转氨酶 (ALT) 和碱性磷酸酶 (ALP) 活性升高以及肾脏内肌酐和尿素水平升高,并破坏肠道微生物群落稳态,增加致病菌丰度而降低 Lactobacillus 等有益菌丰度,还可导致小鼠肝脏、脾脏和肾脏出现显著且呈剂量依赖性的炎症反应。

生物实验数据

生物活性 Dioctyl phthalate (DNOP) is a plasticizer that elevates the activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) in the liver as well as creatinine and urea levels in the kidney, disrupts the homeostasis of the gut microbial community by increasing the abundance of pathogenic bacteria while decreasing that of beneficial bacteria such as Lactobacillus, and induces significant dose-dependent inflammatory responses in the liver, spleen, and kidney of mice.
体内研究
(In Vivo)

Dioctyl phthalate (50-500 mg/kg⋅bw;每日;12 周) 会对幼年 C57BL/6J 雄性小鼠造成剂量依赖性的多器官损伤 (肝、脾、肾、回肠) 和肠道菌群失调,高剂量暴露会导致肝脏 ALT (P < 0.01) 和 ALP (P < 0.001) 水平、脾脏重量 (P < 0.05)、肾脏肌酐 (P < 0.05) 水平显著升高,以及厚壁菌门/拟杆菌门比值降低 (P < 0.05)。
Dioctyl phthalate (50-500 mg/kg⋅bw;每日;12 周) 可诱导老年 C57BL/6J 雄性小鼠出现多器官损伤 (肝脏、脾脏、肾脏、回肠) 及肠道菌群失调,其中高剂量暴露会导致小鼠体重显著下降 (P < 0.05)、肝脏体重比升高 (P < 0.001)、肝脏 ALT (P < 0.01) 和 ALP (P < 0.05) 水平升高、脾脏重量增加 (P < 0.01)、肾脏肌酐水平升高 (P < 0.05),而低剂量组小鼠的厚壁菌门/拟杆菌门比值降低 (P < 0.05)。

Animal Model: C57BL/6J (4-week-old, male, 18-21 g, SPF-grade)
Dosage: 50 mg/kg⋅bw; 500 mg/kg⋅bw
Administration: daily; 12 weeks
Result: Caused sluggishness, lethargy, and decreased vitality in high-dose mice.
Increased body weight compared to controls, with smaller increase in high-dose group than low-dose group (P < 0.01).
Increased liver weight in both low-dose (P > 0.05) and high-dose (P < 0.01) groups compared to controls; increased liver-to-body weight ratio in a dose-dependent manner.
Significantly elevated hepatic ALT (P < 0.01) and ALP (P < 0.001) levels in high-dose group compared to controls.
Significantly increased spleen weight (P < 0.05) and spleen index (P < 0.01) in high-dose group compared to controls, with dose-dependent increases in both parameters.
Significantly elevated creatinine (P < 0.05) levels in high-dose group compared to controls; significantly elevated urea levels (P < 0.05) in both dose groups compared to controls.
Significantly increased serum diamine oxidase (DAO) and D-lactic acid levels in both dose groups compared to controls (P < 0.05).
Decreased Firmicutes relative abundance (50.9% in controls, 44.3% in low-dose, 39% in high-dose) and increased Bacteroidetes abundance (24.8% in controls, 35.9% in low-dose, 38.4% in high-dose) with increasing dose.
Significantly decreased Firmicutes/Bacteroidetes ratio in high-dose group compared to controls (P < 0.05).
Animal Model: C57BL/6J (76-week-old, male, 29-40 g, SPF-grade)
Dosage: 50 mg/kg⋅bw; 500 mg/kg⋅bw
Administration: daily; 12 weeks
Result: Caused sluggishness, lethargy, decreased vitality, and significant weight loss in high-dose mice compared to controls (P < 0.05).
Increased liver weight in both low-dose (P > 0.05) and high-dose (P < 0.05) groups compared to controls; significantly increased liver-to-body weight ratio only in high-dose group (P < 0.001).
Significantly elevated hepatic ALT (P < 0.01) and ALP (P < 0.05) levels in high-dose group compared to controls.
Significantly increased spleen weight (P < 0.01) and spleen index (P < 0.001) in high-dose group compared to controls, with dose-dependent increases in both parameters.
Significantly elevated creatinine (P < 0.05) and urea (P < 0.05) levels in high-dose group compared to controls.
Significantly increased serum diamine oxidase (DAO) levels in high-dose group compared to controls (P < 0.05); significantly increased D-lactic acid levels in both dose groups compared to controls (P < 0.05).
Decreased Firmicutes relative abundance (61.3% in controls, 36.8% in low-dose, 32.4% in high-dose) and increased Bacteroidetes abundance (28.6% in controls, 37.7% in low-dose, 43.9% in high-dose) with increasing dose.
Significantly decreased Firmicutes/Bacteroidetes ratio in low-dose group compared to controls (P < 0.05).
性状 液体(密度:0.978 g/cm3)
颜色 Colorless to light yellow

化学信息

分子量 390.56
分子式 C24H38O4
CAS No. 117-84-0
别名 DNOP; Di-n-octyl phthalate; Phthalic acid dioctyl ester

储存&溶解度

储存方式

Store at room temperature, keep dry and cool

In solvent -80°C 1 year
-20°C 6 months
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (256.04 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.5604 mL12.8021 mL25.6043 mL64.0107 mL
5 mM0.5121 mL2.5604 mL5.1209 mL12.8021 mL
10 mM0.2560 mL1.2802 mL2.5604 mL6.4011 mL
15 mM0.1707 mL0.8535 mL1.7070 mL4.2674 mL
20 mM0.1280 mL0.6401 mL1.2802 mL3.2005 mL
25 mM0.1024 mL0.5121 mL1.0242 mL2.5604 mL
30 mM0.0853 mL0.4267 mL0.8535 mL2.1337 mL
40 mM0.0640 mL0.3201 mL0.6401 mL1.6003 mL
50 mM0.0512 mL0.2560 mL0.5121 mL1.2802 mL
60 mM0.0427 mL0.2134 mL0.4267 mL1.0668 mL
80 mM0.0320 mL0.1600 mL0.3201 mL0.8001 mL
100 mM0.0256 mL0.1280 mL0.2560 mL0.6401 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础